NKTX Nkarta

Nkarta to Participate in an Upcoming Investor Conference

Nkarta to Participate in an Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:

Stifel 2024 Healthcare Conference

November 19, 2024

10:55 a.m. ET – fireside chat

A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, , and a replay will be archived on the website for approximately 90 days.

About Nkarta

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at .

Nkarta Media/Investor Contact:

Greg Mann

Nkarta, Inc.



EN
12/11/2024

Underlying

NKTXNkarta

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nkarta

 PRESS RELEASE
Free
NKTX NKARTA

Nkarta to Participate in an Upcoming Investor Conference

Nkarta to Participate in an Upcoming Investor Conference SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: Stifel 2024 Healthcare ConferenceNovember 19, 202410:55 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, , and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinica...

November 12, 2024 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta Reports Third Quarter 2024 Financial Results and Corporate High...

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studiesEnrollment in Ntrust-2 expected to initiate by year-end 2024 Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025No further NKX019 development in lymphoma planned Platform prioritized to focus on advancement of NKX019 for multiple autoimmune diseases Cash balance of $405.3 million on September 30, 2024, including cash, cash equivalents and investments,...

November 7, 2024 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta to Participate in Upcoming Investor Conference

Nkarta to Participate in Upcoming Investor Conference SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 10, 202412:30 p.m. ET – fireside chat A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, , and a replay will be archived on the website for approximately 90 days. About Nk...

September 3, 2024 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Correction: Nkarta Reports Second Quarter 2024 Financial Results and C...

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitisPreliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025Cash balance of $426.7 million on June 30, 2024, including cash, cash equivalents and investments, expected to fund operations into late 2027 This press release was updated to reflect the correct dosing schedule of the NKX019 investigator-spons...

August 14, 2024 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Hig...

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitisPreliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025Cash balance of $426.7 million on June 30, 2024, including cash, cash equivalents and investments, expected to fund operations into late 2027 SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage bio...

August 13, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch